- FDA clears Rocket Pharmaceuticals' (NASDAQ:RCKT) IND application for RP-L201. RP-L201 is the Company’s lentiviral vector-based gene therapy for the treatment of severe Leukocyte Adhesion Deficiency-I (LAD-I) that was in-licensed from the Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT).
- This IND enables Rocket to initiate a Phase 1/2 clinical trial to assess the safety, tolerability, and efficacy of severe LAD-I in children.
FDA cleared Rocket Pharmaceuticals' IND for RP-L201
Recommended For You
More Trending News
About RCKT Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
RCKT | - | - |
Rocket Pharmaceuticals, Inc. |